(ShareCast News) - Shares in Akers Biosciences rose on Monday after the health technology company said it has begun marketing its test for heparin-induced thrombocytopenia (HIT) to some hospitals in Puerto Rico as part of its strategy to accelerate US sales of its product.
The Nasdaq and AIM-listed company believes that...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE